Phathom Pharmaceuticals, Inc.
PHAT
$11.03
$0.6456.21%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 439.36% | 1,391.58% | 4,249.56% | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 439.36% | 1,391.58% | 4,249.56% | -- | -- |
| Cost of Revenue | 266.13% | 774.18% | 2,184.43% | -- | -- |
| Gross Profit | 479.44% | 1,568.57% | 4,919.22% | -- | -- |
| SG&A Expenses | 12.44% | 52.35% | 34.54% | 225.27% | 300.65% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 17.49% | 49.42% | 26.25% | 144.39% | 166.94% |
| Operating Income | 22.48% | -12.74% | 14.97% | -98.54% | -143.84% |
| Income Before Tax | 17.10% | -13.84% | 6.43% | -97.90% | -123.23% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 17.10% | -13.84% | 6.43% | -97.90% | -123.23% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 17.10% | -13.84% | 6.43% | -97.90% | -123.23% |
| EBIT | 22.48% | -12.74% | 14.97% | -98.54% | -143.84% |
| EBITDA | 22.50% | -12.83% | 15.02% | -98.67% | -144.17% |
| EPS Basic | 33.01% | 7.67% | 24.55% | -73.87% | -84.89% |
| Normalized Basic EPS | 33.01% | 7.67% | 24.54% | -73.87% | -84.88% |
| EPS Diluted | 33.01% | 7.67% | 24.55% | -73.87% | -84.89% |
| Normalized Diluted EPS | 33.01% | 7.67% | 24.54% | -73.87% | -84.88% |
| Average Basic Shares Outstanding | 23.75% | 23.30% | 24.00% | 13.82% | 20.74% |
| Average Diluted Shares Outstanding | 23.75% | 23.30% | 24.00% | 13.82% | 20.74% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |